CD27 is a member of the tumour necrosis factor receptor superfamily. This receptor is required for generation and long-term maintenance of T cell immunity. It binds to ligand CD70, and plays a key role in regulating B-cell activation and immunoglobulin synthesis. This receptor transduces signals that lead to the activation of NF-<U+03BA>B and MAPK8/JNK
| Institute |
|---|
| Netherlands Cancer Institute |
| Cat. #: | 154728 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Cell signaling and signal transduction;Immunology |
| Application: | ELISA ; FACS ; IHC ; IP |
| Target: | CD27 |
| Reactivity: | Human ; Mouse |
| Host: | Hamster |
| Class: | Monoclonal |
| Alternate name: | Tumor Necrosis Factor Receptor Superfamily, Member 7; TNFRSF7 |
|---|---|
| Product description: | CD27 is a member of the tumour necrosis factor receptor superfamily. This receptor is required for generation and long-term maintenance of T cell immunity. It binds to ligand CD70, and plays a key role in regulating B-cell activation and immunoglobulin synthesis. This receptor transduces signals that lead to the activation of NF-ÄÂ?B and MAPK8/JNK |
| Conjugation: | Unconjugated |
| Isotype: | IgG |
| Molecular weight: | 55 kDa |
| Immunogen: | Armenian hamster fibroblasts transfected with the mouse CD27 DNA. Screened on same transfectants. |
| Myeloma used: | Sp2/0-Ag14 |
| Target background: | CD27 is a member of the tumour necrosis factor receptor superfamily. This receptor is required for generation and long-term maintenance of T cell immunity. It binds to ligand CD70, and plays a key role in regulating B-cell activation and immunoglobulin synthesis. This receptor transduces signals that lead to the activation of NF-B and MAPK8/JNK |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -20° C |
| Shipping conditions: | Dry ice |
| References: |
Hendriks et al. 2000. Nat Immunol. 1(5):433-40. PMID: 11062504. Gravestein et al. 1996. J Exp Med. 184(2):675-85. PMID: 8760821. Gravestein et al. 1995. Int Immunol. 7(4):551-7. PMID: 7547681. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151019 | Anti-Mos [S3.1] |
Key Info
Anti-Mos [S3.1]
|
View Tool | |||||||||||||||||||
| 151024 | Anti-Hairy [1/24] |
Key Info
Anti-Hairy [1/24]
|
View Tool | |||||||||||||||||||
| 151026 | Anti-FCGR1 [10.1] mAb |
Key Info
Anti-FCGR1 [10.1] mAb
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
| 151038 | Anti-Cytochrome P450 4A2, 4A3 [Clo4] |
Key Info
Anti-Cytochrome P450 4A2, 4A3 [Clo4]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.